A new generation of COVID-19 vaccines – the latest developments from preclinical and clinical trials?

In the UK Government strategy ‘Living with COVID’, COVID-19 vaccines represent the first line of defence against SARS-CoV-2. Advances in vaccine technologies allowed manufacturers to develop the first generation of COVID-19 vaccines in record time (see Research from the House of Commons Library and POST on COVID-19 vaccines). Current vaccines are highly effective against hospitalisation […]

Read More

Stablepharma Ltd has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible

Stablepharma has achieved an important milestone with the Td-StablevaX-M™, having successfully demonstrated stability of the reformulated Td vaccine for up to 10 months at +45ºC in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio). Td-StablevaX-M™ is a pre-filled disposable syringe containing dry stabilised tetanus diptheria vaccine for administration by injection following rehydration. Results demonstrate […]

Read More

Stablepharma Ltd welcomes another new member to the UK Team

Anh Go joins the company as Strategy and Operations Manager and brings a wealth of diverse and cross-sector experience from healthcare, life science and government. Prior to joining Stablepharma, Anh was part of the Healthcare and Life Sciences Consulting Practice at KPMG in the UK and Australia, where she focused on managing global patient pathway […]

Read More

Daniela Maria Briceño Garcia joins the Stablepharma Science Team

Stablepharma is delighted to announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s Centre of Excellence (CoE) in Qube Technology Park.  With a Bachelors degree in Chemistry from the Universidad de Los Andes – Venezuela and a Biochemistry Master’s Degree from Harvard University, Daniela Briceño Garcia has more than 15 […]

Read More

Stablepharma completes the first close of Series A raise with £2 million following a number of high-profile partnership announcements

UK-based biotech aims to be the first fridge-free vaccine company in the world. Stablepharma Ltd, a UK-based biotech who have a novel technology platform for fridge-free vaccines, has announced the completion of the first close of their Series A, with £2 million. Funding came from existing shareholders and new investors such as Ascension Ventures and […]

Read More

Alan Boyd, of Boyd Consultants & Advisor to Stablepharma, talks about his work, collaborations and the impact of the Pandemic

I recently interviewed Professor Alan Boyd, of Boyd Consultants, Fellow of the Academy of Medical Sciences and a member of the Stablepharma Ltd Advisory Board. We covered such topics as his work with the University of Oxford & AstraZenca on the COVID-19 programme, Boyds collaboration with Wellcome on a COVID-19 human infection study and Alan’s […]

Read More